Business
Todos Medical Releases Preliminary Data From IRB-Waived Tollovid® Market Research Study in Acute and Long COVID
Todos Medical Releases Preliminary Data From IRB-Waived Tollovid® Market Research Study in Acute and Long COVID.
About this update from Todos Medical Ltd.
[{"type":"text","content":"\n 83% of Respondents With Acute COVID Were Satisfied 68% of Respondents With Long COVID Were Satisfied NEW YORK, NY, and TEL AVIV, ISRAEL, June 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced preliminary data from its majority-owned joint venture 3CL Pharma Ltd.’s ongoing IRB-waived sponsored market research study of the commercial use of Tollovid® as a dietary supplement. Among the first 41 respondents, of whom 78% were fully vaccinated against COVID-19, 13 reported that they began to use Tollovid when they were diagnosed with active COVID infection, whereas 28 respondents reported that they used Tollovid to address their Long COVID symptoms. 15 of the Long COVID respondents had experienced symptoms for up to 9 months (‘Short’ Long COVID), and 12 of the Long COVID respondents reported having symptoms for over 9 months (‘Chronic’ Long COVID). 18 of the 24 respondents who answered the question “Who diagnosed your Long COVID?” indicated that they were diagnosed by a medical professional. The preliminary results of the market research study are marked in the table below: Overall Satisfaction% w/Improved Symptoms Happy with their resultsAcute COVID100.00%83.00%Short Long COVID93.70%87.50%Chronic Long COVID41.60%41.60%   Key Symptoms RelievedSymptom #1Symptom #2Acute COVIDFatigue - 72.7%Congestion - 63.6%Short Long COVIDFatigue - 91.6%Headaches - 77.7%Chronic Long COVIDFatigue - 50% Headaches - 40%   Reported Side Effects (≥5%)Dark StoolMuscle Twitching  17%5% *  Tollovid® is not approved to diagnose, treat, prevent or cure any disease, including COVID and/or Long COVID “We are pleased with the preliminary results from this sponsored market research study that show the majority of our customers are satisfied with Tollovid,” said Dr. Dorit Arad, Founder and Chief Scientific Officer at 3CL Pharma. “As we add to the growing body of information related to COVID, Long COVID and 3CL protease inhibitor products, we believe the knowledge gained from this market research study will allow us to tailor our offering to meet the needs of the immune competent (not immune compromised) and Long CO...